Related Experiment Video

Updated: Jun 5, 2026

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

Therapeutic potential for protein kinase C inhibitor in vascular restenosis

Richard Qinxue Ding1, Jerry Tsao, Hong Chai

  • 1Division of Vascular and Endovascular Surgery, Department of Surgery, Stanford University, Stanford, CA 94350, USA.

Journal of Cardiovascular Pharmacology and Therapeutics
|December 25, 2010
PubMed

Insights

Protein kinase C (PKC) inhibitors show therapeutic potential for vascular restenosis by targeting key cellular responses like smooth muscle cell proliferation. This review explores PKC isozymes

Area of Science:

  • Cardiovascular Biology
  • Pharmacology
  • Cellular Signaling

Background:

  • Vascular restenosis involves thrombosis, inflammation, and smooth muscle cell (SMC) migration/proliferation following injury.
  • Current treatments for restenosis include anticoagulants, antiplatelet agents, immunosuppressants, and antiproliferation agents.
  • Protein kinase C (PKC) is implicated in various pathological stages of restenosis.

Purpose of the Study:

  • To review the role of Protein Kinase C (PKC) isozymes in the cellular mechanisms of vascular restenosis.
  • To discuss the therapeutic potential of PKC inhibitors in preventing restenosis.
  • To evaluate the efficacy and safety of PKC inhibitors targeting specific isozymes.

Main Methods:

  • Review of cellular and animal studies on PKC involvement in restenosis.
  • Analysis of PKC isozyme functions in platelets, leukocytes, endothelial cells, and SMCs, with a focus on SMCs.
  • Assessment of studies evaluating PKC inhibitors, particularly targeting PKC-α, -β, -δ, and -ζ.

Main Results:

  • PKC isozymes play critical roles in the cellular processes contributing to vascular restenosis.
  • PKC inhibitors targeting specific isozymes have demonstrated preventative effects in cellular and animal models.
  • Delivery strategies, efficacy, and safety profiles of PKC inhibitors are key considerations for therapeutic application.

Conclusions:

  • PKC signaling pathways are crucial in the pathogenesis of vascular restenosis.
  • Targeting specific PKC isozymes with inhibitors offers a promising therapeutic strategy for preventing restenosis.
  • Further research into delivery, efficacy, and safety is warranted for clinical translation of PKC inhibitors.

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

A Microphysiological System to Study Leukocyte-Endothelial Cell Interaction during Inflammation12:55

A Microphysiological System to Study Leukocyte-Endothelial Cell Interaction during Inflammation

Published on: December 9, 2021

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...